Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma

Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma

Abstract Background The introduction of immune checkpoint inhibitors has led to a survival benefit in patients with advanced melanoma; however data on the adoption of immunotherapy in the community are scarce. Methods Using the National Cancer Database, we identified 4725 patients aged ≥20 diagnosed...

Full description

Bibliographic Details
Main Authors: Marieke J. Krimphove, Karl H. Tully, David F. Friedlander, Maya Marchese, Praful Ravi, Stuart R. Lipsitz, Kerry L. Kilbridge, Adam S. Kibel, Luis A. Kluth, Patrick A. Ott, Toni K. Choueiri, Quoc-Dien Trinh
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Metastatic melanoma
Immunotherapy
Checkpoint inhibitors
Health services research
Ipilimumab
Online Access:http://link.springer.com/article/10.1186/s40425-019-0782-y

Internet

http://link.springer.com/article/10.1186/s40425-019-0782-y

Similar Items